1. Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?
- Author
-
Németh B, Péter I, Boncz I, Jagicza A, Kiss I, Csergő Á, Kőszegi T, Kustán P, Horváth IG, and Ajtay Z
- Subjects
psoriasis ,orosomucoid ,oxidative stress ,C-reactive protein ,biomarker ,cardiovascular risk ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Balázs Németh,1,2 Iván Péter,1 Imre Boncz,1 Anna Jagicza,1 István Kiss,2 Ágnes Csergő,2 Tamás Kőszegi,3,4 Péter Kustán,3,4 Iván G Horváth,5 Zénó Ajtay1,51Dermatology Unit, Zsigmondy Vilmos SPA Hospital, Harkány, Hungary; 2Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary; 3Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary; 4János Szentágothai Research Centre, University of Pécs, Pécs, Hungary; 5Heart Institute, Medical School, University of Pécs, Pécs, HungaryPurpose: Psoriasis is one of the most common lifelong lasting dermatologic diseases. According to the latest studies, psoriatic patients have a higher risk of developing cardiovascular diseases. Psoriasis is considered as a systemic inflammatory disease. Several oxidative stress markers have been shown to be elevated in psoriasis. However, a panel of biomarkers has not been used yet. This study was aimed at exploring the connection between a panel of biomarkers (C-reactive protein, asymmetric dimethylarginine, uric acid, total antioxidant capacity, malondialdehyde, and orosomucoid [ORM]) and cardiovascular risk in psoriatic patients.Patients and methods: The inclusion criterion was the onset of psoriasis with skin lesions. Exclusion criteria were impaired renal function (eGFR
- Published
- 2019